Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2870723 | 0.91 | MEN1 (0.39) | NPSR1KMT2AMEN1FAAHMAPT | |
| SCHEMBL2864826 | 0.91 | F10 (0.40) | NPSR1LMNAFAAHPOLB | |
| SCHEMBL2863274 | 0.89 | ALDH1A1 (0.41) | NPSR1KMT2AMEN1TSHRMAPT | |
| SCHEMBL2861932 | 0.89 | ALDH1A1 (0.39) | NPSR1LMNAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2862405 | 0.88 | EP300 (0.47) | LMNAGRIN2BKMT2AMEN1MAPT | |
| SCHEMBL2862278 | 0.87 | GRIN2B (0.43) | GRIN2BKMT2AMEN1TSHRMAPT | |
| SCHEMBL2858289 | 0.87 | RAB9A (0.39) | NPSR1LMNAKMT2AMEN1TSHR | |
| SCHEMBL2860452 | 0.86 | GRIN2B (0.43) | NPSR1GRIN2BMAPTSMN1; SMN2 | |
| SCHEMBL2856315 | 0.86 | NPSR1 (0.58) | NPSR1KMT2AMEN1TSHRPOLB | |
| SCHEMBL2861976 | 0.85 | ALDH1A1 (0.40) | NPSR1LMNAKMT2AMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | NPSR1 211/4885LMNA 4583/4885GRIN2B 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.